McKesson Corporation (MCK)
$
712.13
-8.25 (-1.16%)
Key metrics
Financial statements
Free cash flow per share
44.8163
Market cap
89.1 Billion
Price to sales ratio
0.2481
Debt to equity
-3.5632
Current ratio
0.8993
Income quality
1.7481
Average inventory
23.4 Billion
ROE
-1.3273
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
McKesson Corporation, founded in 1833 and headquartered in Irving, Texas, provides a wide range of healthcare services both in the United States and internationally. The company operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment is involved in the distribution of branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, along with other healthcare-related products. Additionally, this segment offers practice management, technology, clinical support, and business solutions tailored for community-based oncology and other specialty practices. It also provides consulting, outsourcing, technological, and various services while selling financial, operational, and clinical solutions to pharmacies. The International segment serves wholesale, institutional, and retail customers across 13 European countries and Canada. The Medical-Surgical Solutions segment focuses on distributing medical-surgical supplies, logistics, and other essential services to healthcare providers. Meanwhile, the RxTS segment caters to biopharma and life sciences partners, addressing medication challenges throughout patient journeys; it connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions while also providing third-party logistics and wholesale distribution support solutions. The company reported depreciation and amortization expenses of $636,000,000.00 reflecting the wear and tear of its assets. Its selling, general, and administrative expenses total $8,507,000,000.00 indicating operational overhead costs. The interest income earned amounting to $173,000,000.00 showcases its financial investments. Overall, the total costs and expenses for the company are $354,629,000,000.00 reflecting comprehensive spending, while the EBITDA stands at $5,260,000,000.00 a key indicator of the company's operational profitability. In the financial marketplace, the stock is priced at $712.13 positioning it in the higher-end market. It has an average trading volume of 1,083,101.00 indicating moderate liquidity in its trading activities. With a significant market capitalization of $89,096,008,560.00 McKesson Corporation establishes itself as a dominant player in the healthcare industry. The company is an essential participant in the Medical - Distribution industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its domain.
Is McKesson Corporation (MCK) a good investment?
Investing in McKesson Corporation (MCK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is McKesson Corporation (MCK)'s stock forecast?
Analysts predict McKesson Corporation stock to fluctuate between $464.42 (low) and $731 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is McKesson Corporation's market capitalization?
As of 2025-05-29, McKesson Corporation's market cap is $89,096,008,560, based on 125,112,000 outstanding shares.
How does McKesson Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., McKesson Corporation has a Lower Market-Cap, indicating a difference in performance.
Does McKesson Corporation pay dividends?
McKesson Corporation pays dividends. The current dividend yield is 0.40%, with a payout of $0.71 per share.
How can I buy McKesson Corporation (MCK) stock?
To buy McKesson Corporation (MCK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MCK. Place an order (Market, Limit, etc.).
What is the best time to invest in McKesson Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has McKesson Corporation stock ever split?
McKesson Corporation's last stock split was 2:1 on 1998-01-05.
How did McKesson Corporation perform in the last earnings report?
Revenue: $359,051,000,000 | EPS: $25.86 | Growth: 14.73%.
Where can I find McKesson Corporation's investor relations reports?
Visit https://www.mckesson.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for McKesson Corporation?
You can explore historical data from here
What is the all-time high and low for McKesson Corporation stock?
All-time high: $731 (2025-05-20) | All-time low: $169.34 (2021-02-26).
What are the key trends affecting McKesson Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.
zacks.com
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
seekingalpha.com
The stock price of McKesson has maintained a strong upward trend throughout multiple years because of its solid financial performance and dedicated investor support which creates a defensive investment opportunity. The company achieves strong revenue and EPS growth through its expanding oncology, biopharmaceutical and GLP-1 therapy sales, which counterbalance the typical thin margins of the sector. The company's strategic focus on high-growth segments together with its divestment of slow-growth units makes McKesson an attractive long-term investment despite its high valuation and low yield.
forbes.com
Deal OverviewOn May 8, 2025, McKesson Corporation (NYSE: MCK, $682.28, Market Capitalization: $85.4 billion), a diversified healthcare services company, announced its intention to separate its Medical-Surgical Solutions segment into an independent company (NewCo) (for more information, visit spinoffresearch.com). McKesson is committed to exploring all opportunities to execute a separation in a manner that maximizes shareholder value and anticipates providing more information as appropriate on the form and timing as the process progresses.
zacks.com
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
seekingalpha.com
McKesson Corporation (NYSE:MCK ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:00 AM ET Company Participants Britt Vitalone - Chief Financial Officer Conference Call Participants Allen Lutz - Bank of America Allen Lutz Welcome to day one of the BofA Healthcare Conference here in Las Vegas. We are very excited to welcome McKesson here.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
fool.com
Storied healthcare supplies company McKesson (MCK 0.34%) was a slight outperformer on the stock exchange Friday, as investors considered its results for its fourth quarter of fiscal 2025. They liked, if not loved, what they saw, sending the shares to a 0.5% gain on that day.
seekingalpha.com
I reiterate a Strong Buy rating on McKesson Corporation with a fair value of $828 per share, driven by robust growth in the oncology and biopharma sectors. McKesson posted 19% revenue growth and 63.8% adj. EPS growth, largely driven by strong demand for GLP-1 products, which now represent 12% of total revenue. The company's global supply chain flexibility and non-discretionary drug pricing render it largely immune to tariff uncertainties, ensuring stable future growth.
See all news
